The implementation of immunotherapies with checkpoint inhibitors has substantially improved therapeutic outcomes of patients with advanced or metastatic non–small-cell lung cancer (NSCLC). In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results